In vitro study reveal susceptibility of human ovarian cells to infection’s spike (& thus to vaxx’s spike), suggesting a detrimental effect on births, female human fecundity & fertility of COVID vaxx

A massive fertility (fecundity) decline is coming and may have started already! We are at risk now of a dramatic drop in birth rates. 

SOURCE:

SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility

The deleterious role of the spike protein induced by COVID vaccine must be centered in this debate given these findings on how the virus gains entry into ovarian cells. What is critical for us to grasp is that when the vaccine’s content is taken up into heart cells as an example, and the spike protein is translated from mRNA contained in the lipid nano-particles (LNP), the spike protein migrates and then sits on the surface of the cells e.g. heart myocardial cells, or even on the surface of endothelial cells (if produced there) that line the cardiovascular system (inner vessel walls, then protrude into the blood flow, causing clots, bleeding and attack). And being foreign proteins the spike protein are targets and attacked by the body e.g. killer lymphocytes etc. 

This study raises the real potential for severe spike injury to ovarian cells in women and devastating fertility issues that are coming. 

This is the process that in involved in reported blood clots and bleedings post COVID vaccine. This very process can thus occur in female reproductive cells based on this study findings, we have to infer this. If the COVID virus can use the spike protein to gain entry via the ACE 2 receptor and it is shown here in ovarian cells etc. (we know that ovaries and endometrium cells contain ACE 2) and thus massive risk for fertility problems in women, then the same synthetic spike protein induced from the COVID injection, can potentially interact with the ACE 2 and cause the reproductive cells to come under attack as explained above. As well LNP and mRNA may be taken up by these reproductive cells, produce spike protein and the cells would be targeted by the body’s defense system. We have to speculate then that this could disturb ovarian function, and potentially impact fertility and reproductive outcomes. 

“Indeed, in humans, ACE2 expression has been detected in many organs, such as the respiratory tract, the gastrointestinal system, the kidney, heart, uterus, testis and placenta [9]. Noteworthy is that ACE2 is highly expressed in the human ovaries and in the stromal endometrial cells, as well as in granulosa cells (GCs) and oocytes in rat ovaries [9,10]. The expression of ACE2 is reported in the ovaries of reproductive-age and post-menopausal women [9], thus suggesting that the female reproductive system is potentially at risk of SARS-CoV-2 infection….

Two distinct routes for SARS-COV-2 entry, dependent on the target-cell proteases, have been reported [2]. After ACE2 binding, S protein activation may occur at the plasma membrane, where TMPRSS2 is expressed, whereas cathepsin-mediated activation occurs in the endosomal route, where TMPRSS2 is not present. Of note, some variants such as Omicron are capable of efficiently entering cells in a TMPRSS2-independent manner, via the endosomal route [26].

In this study, for the first time, we provide clear evidence of SARS-CoV-2 infection in granulosa and cumulus cells, the ovarian somatic cells that support oocyte development and competence acquisition. By detecting RNA, proteins and viral particles at ultrastructural level, we proved that these cells express the specific receptor ACE2 and the corresponding proteases TMPRSS2, BSG and CTSL, which allow the entry of this coronavirus into the host cell, by interacting in a coordinated manner with the viral spike protein…

This study provides the first biological explanation for the recently reported evidence that infection with SARS-CoV-2 could impair ovarian function, thus potentially affecting reproductive outcomes.”

Important additional source

Source – https://palexander.substack.com/p/fertility-concerns-for-women-with